(Rac) -Roscovitine

(Rac) -Roscovitine ((Rac) -Seliciclib) is a selective cyclin-dependent kinases (CDKs) inhibitor. (Rac) -Roscovitine binds to the active sites of CDKs competitively with ATP, inhibiting the phosphorylation activity of CDKs. (Rac) -Roscovitine induces apoptosis in cancer cells. (Rac) -Roscovitine is promising for research of cancers or other diseases associated with CDK dysregulation, such as neurodegenerative diseases, cardiac disorders, viral and protozoan infections, glomerulonephritis, and chronic inflammation[1].

Product Specifications

CAS Number

[186692-44-4]

Product Name Alternative

(Rac) -Seliciclib; (Rac) -CYC202

UNSPSC

12352005

Hazard Statement

H315-H319

Target

Apoptosis; CDK

Related Pathways

Apoptosis; Cell Cycle/DNA Damage

Applications

COVID-19-anti-virus

Field of Research

Cancer; Infection; Inflammation/Immunology; Neurological Disease; Cardiovascular Disease

Smiles

CCC(NC1=NC(NCC2=CC=CC=C2)=C3N=CN(C(C)C)C3=N1)CO

Molecular Formula

C19H26N6O

Molecular Weight

354.45

Precautions

P264-P280-P302+P352-P362+P364

References & Citations

[1]Jorda R, et al. Pyrazolo[4,3-d]pyrimidine bioisostere of roscovitine: evaluation of a novel selective inhibitor of cyclin-dependent kinases with antiproliferative activity. J Med Chem. 2011 Apr 28;54 (8) :2980-93.